得克萨斯州 的 结直肠癌 临床试验
得克萨斯州 有 146 项针对 结直肠癌 的研究正在招募参与者。
得克萨斯州 的城市
- Houston103 项研究
- San Antonio46 项研究
- Dallas33 项研究
- Austin19 项研究
- Irving13 项研究
- Tyler8 项研究
- Fort Worth7 项研究
- Killeen6 项研究
- League City6 项研究
- Abilene5 项研究
- The Woodlands5 项研究
- Arlington3 项研究
- Lewisville3 项研究
- Round Rock3 项研究
- Amarillo3 项研究
官方研究文本（英文）
A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors
- ALX Center 5, Houston
招募中1 期
18 岁及以上 · 所有性别 · 更新于 2026年9月30日 · NCT07085091Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
- The Methodist Hospital Research Institute, Houston
- The University of Texas MD Anderson Cancer Center, Houston
招募中1/2 期
18 岁及以上 · 所有性别 · 更新于 2026年9月30日 · NCT06324357177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
- MD Anderson Cancer Center, Houston
招募中1/2 期
18 岁及以上 · 所有性别 · 更新于 2026年9月30日 · NCT07189871A Phase 1 Study of IM-1617 in Participants With Advanced Cancer
- NEXT Dallas, Irving
招募中1 期
18 岁及以上 · 所有性别 · 更新于 2026年9月29日 · NCT07578571Testing the Combination of Anti-Cancer Drugs, Botensilimab (AGEN1181) and Balstilimab (AGEN2034), After Standard Treatment for Colorectal Cancer, Combat Trial
- UT MD Anderson Cancer Center, Houston
招募中2 期
18 岁及以上 · 所有性别 · 更新于 2026年9月29日 · NCT07551596A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
- Research Site, Houston
- Research Site, Round Rock
招募中1 期
18 岁及以上 · 所有性别 · 更新于 2026年9月29日 · NCT05877599A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer
- START Dallas Fort Worth, Fort Worth
- The University of Texas MD Anderson Cancer Center, Houston
招募中2 期
18 岁及以上 · 所有性别 · 更新于 2026年9月29日 · NCT07659795Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or Targeted Therapy and/or ICI, for the Treatment of Patients With Advanced Gastrointestinal Cancers, Including Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)
- MD Anderson Cancer Center, GI Medical Oncology Dept, Houston
招募中1/2 期
18 岁及以上 · 所有性别 · 更新于 2026年9月28日 · NCT05482893A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer
- Texas Oncology - Abilene - Antilley Road /ID# 280120, Abilene
- The University of Texas MD Anderson Cancer Center /ID# 279865, Houston
招募中3 期
18 岁及以上 · 所有性别 · 更新于 2026年9月28日 · NCT07525206A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer
- Texas Oncology - Austin Midtown /ID# 271354, Austin
- Texas Oncology - Deke Slayton Cancer Center /ID# 271355, Webster
招募中2 期
18 岁及以上 · 所有性别 · 更新于 2026年9月28日 · NCT06820463Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
- Texas Oncology - West Texas, Abilene
- Texas Oncology - West Texas, Amarillo
- Texas Oncology - Gulf Coast, Beaumont
- 以及另外 27 项
招募中3 期
18 岁及以上 · 所有性别 · 更新于 2026年9月28日 · NCT07222800A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer
- MD Anderson Cancer Center, Houston
招募中1/2 期
18 岁及以上 · 所有性别 · 更新于 2026年9月25日 · NCT05379595A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
- Texas Oncology West Texas, Abilene
- Texas Oncology DFW, Dallas
- UT Southwestern, Dallas
- 以及另外 4 项
招募中3 期
18 岁及以上 · 所有性别 · 更新于 2026年9月25日 · NCT06662786Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
- Research Site, Dallas
- Research Site, Galveston
- Research Site, Houston
招募中1 期
18 岁及以上 · 所有性别 · 更新于 2026年9月25日 · NCT06218914A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
- Texas Oncology West Texas, Abilene
- Parkland Health and Hospital System, Dallas
- Texas Oncology DFW, Dallas
- 以及另外 6 项
招募中3 期
18 岁及以上 · 所有性别 · 更新于 2026年9月25日 · NCT06750094A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors
- MD Anderson Cancer Center, Houston
- START San Antonio, San Antonio
招募中1 期
18 岁及以上 · 所有性别 · 更新于 2026年9月25日 · NCT06004245A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)
- University of Texas MD Anderson Cancer Center ( Site 0316), Houston
招募中1/2 期
18 岁及以上 · 所有性别 · 更新于 2026年9月25日 · NCT06428409A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tumors
- GSK Investigational Site, Dallas
招募中1 期
18 岁及以上 · 所有性别 · 更新于 2026年9月25日 · NCT07277270Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial
- Parkland Memorial Hospital, Dallas
- UT Southwestern Simmons Cancer Center - RedBird, Dallas
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
- 以及另外 2 项
招募中3 期
18 岁及以上 · 所有性别 · 更新于 2026年9月24日 · NCT05863195Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
- Baylor, Scott and White Research Institute, Dallas
招募中1/2 期
18 岁及以上 · 所有性别 · 更新于 2026年9月24日 · NCT06047379A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer
- Texas Oncology Dallas Fort Worth West (DFWW) - Arlington Cancer Center North, Arlington
- Texas Oncology, PA, Austin
- Baylor College of Medicine Medical Center, Houston
- 以及另外 1 项
招募中2/3 期
18 岁及以上 · 所有性别 · 更新于 2026年9月23日 · NCT07221357Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer
- UT MD Anderson Cancer Center, Houston
招募中1 期
18 岁及以上 · 所有性别 · 更新于 2026年9月23日 · NCT06102902Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
- Research Site, Houston
招募中2 期
18 至 130 岁 · 所有性别 · 更新于 2026年9月23日 · NCT05489211Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
- MD Anderson, Houston
- NEXT Dallas, Irving
- NEXT Oncology San Antonio, San Antonio
- 以及另外 1 项
招募中1/2 期
18 岁及以上 · 所有性别 · 更新于 2026年9月22日 · NCT06128551Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
- Baylor College of Medicine, Houston
- The University of Texas MD Anderson Cancer Center, Houston
- NEXT Oncology Dallas, Irving
招募中1/2 期
18 岁及以上 · 所有性别 · 更新于 2026年9月22日 · NCT06445062A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
- Texas Oncology - DFW (Sammons CC), Dallas
- Baylor College of Medicine, Houston
招募中1 期
18 岁及以上 · 所有性别 · 更新于 2026年9月22日 · NCT07213791A Study of LY4257496 in Participants With Cancer (OMNIRAY)
- Texas Oncology - DFW (Sammons CC), Dallas
- MD Anderson Cancer Center, Houston
招募中1 期
18 岁及以上 · 所有性别 · 更新于 2026年9月22日 · NCT07114601A Study to Assess Safety and Efficacy of SOT109 in Patients With Advanced Unresectable or Metastatic Colorectal Cancer
- NEXT Houston, Houston
招募中1/2 期
18 岁及以上 · 所有性别 · 更新于 2026年9月21日 · NCT07693751A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
- The University of Texas MD Anderson Cancer Center - Texas Medical Center, Houston
招募中1/2 期
18 岁及以上 · 所有性别 · 更新于 2026年9月21日 · NCT07629960Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
- NEXT - Dallas, Dallas
- NEXT, San Antonio
- START - San Antonio, San Antonio
招募中1 期
18 岁及以上 · 所有性别 · 更新于 2026年9月17日 · NCT07349537TAS-102 With or Without Celecoxib in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy
- MD Anderson Cancer Center, Houston
招募中2 期
18 岁及以上 · 所有性别 · 更新于 2026年9月16日 · NCT05343013Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
- MD Anderson Cancer Center, Houston
- START San Antonio, San Antonio
招募中1/2 期
18 岁及以上 · 所有性别 · 更新于 2026年9月16日 · NCT05786924The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- New Experimental Therapeutics - NEXT Oncology, Austin
- Texas Oncology, Bedford
- UT Southwest Simmons Cancer Center, Dallas
- 以及另外 2 项
招募中1/2 期
12 岁及以上 · 所有性别 · 更新于 2026年9月15日 · NCT04585750A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
- Ascension Seton Spclty Care Ctr, Austin
- Texas Oncology, Austin
- University of Texas Southwestern Medical Center, Dallas
- 以及另外 2 项
招募中3 期
18 岁及以上 · 所有性别 · 更新于 2026年9月15日 · NCT07284849Open-label Phase 1b Study of Ulixertinib and Cetuximab or Ulixertinib in Combination With Cetuximab and Encorafenib in Patients With Unresectable or Metastatic Colorectal Cancer Who Have Previously Received EGFR or BRAF-directed Therapy
- M D Anderson Cancer Center, Houston
招募中1 期
18 岁及以上 · 所有性别 · 更新于 2026年9月11日 · NCT05985954A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)
- Texas Oncology - Northeast Texas, Denton
- Texas Oncology - Gulf Coast, Webster
招募中1 期
18 岁及以上 · 所有性别 · 更新于 2026年9月11日 · NCT04929223A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)
- Texas Oncology, P.A. - Abilene - 300210366, Abilene
- Texas Oncology-South Austin, Austin
- Texas Oncology DFW, Bedford
- 以及另外 2 项
招募中3 期
18 岁及以上 · 所有性别 · 更新于 2026年9月9日 · NCT07549412A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors
- UT MD Anderson, Houston
- NEXT Oncology, San Antonio
招募中1 期
18 岁及以上 · 所有性别 · 更新于 2026年9月9日 · NCT06440005Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
- SCRI at Mary Crowley, Dallas
- University of Texas Southwestern Medical Center, Dallas
- The University of Texas MD Anderson Cancer Center, Houston
- 以及另外 1 项
招募中1 期
18 岁及以上 · 所有性别 · 更新于 2026年9月9日 · NCT06625775Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer
- Clinical Study Site, Dallas
- Clinical Study Site, Dallas
- Clinical Study Site, Fort Worth
- 以及另外 3 项
招募中3 期
18 岁及以上 · 所有性别 · 更新于 2026年9月8日 · NCT07228832数据来自 ClinicalTrials.gov，检索日期：2026年10月1日。每项研究自行设定入选标准，由研究团队决定谁能参与。